– USA, CA – Exai Bio, a next-generation RNA- and AI-based liquid biopsy company, announced the appointment of Dr. Karen Knudsen (Ph.D.) to its board of directors.
About Dr. Karen E. Knudsen
Dr. Karen Knudsen is the former CEO of the American Cancer Society and its affiliate, the American Cancer Society Cancer Action Network. She is an internationally recognized leader in oncology research and patient advocacy, and a healthcare executive dedicated to the goal of ending cancer as we know it for everyone.
Dr. Karen Knudsen transformed ACS to improve the lives of cancer patients and fueled a period of remarkable growth, including the development of strategic partnerships that accelerated access to cancer breakthroughs. Before ACS, Knudsen served as executive vice president of oncology services and enterprise director of the NCI-designated Sidney Kimmel Comprehensive Cancer Center at Jefferson Health, recognized for its research and impact on cancer outcomes. She also served as president of the Association of American Cancer Institutes, representing the 106 major cancer centers in North America, and on the National Cancer Institute’s Board of Scientific Advisors. She has authored over 200 peer-reviewed publications and is well known for her paradigm-shifting and translational cancer discoveries.
“I’m thrilled to join the board of Exai, where we are focused on the critical challenge of breast cancer detection for women with dense breast tissue,” said Dr. Karen Knudsen. “Traditional screening methods often fall short for these women, who are at higher risk. The need is particularly urgent, as there is an alarming trend of younger women being diagnosed with breast cancer. To truly achieve ending cancer as we know it, we must focus on both prevention and early detection of meaningful cancers.”
About Exai Bio
Exai Bio is a next-generation liquid biopsy company. Its mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured. The company’s proprietary oncRNA- and AI-based liquid biopsy technology delivers clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer.
For more information: https://www.exai.bio/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.